Accueil   Diary - News   All news ELSALYS BIOTECH acquires from JAZZ PHARMACEUTICALS the worldwide rights of LEUKOTAC®

ELSALYS BIOTECH acquires from JAZZ PHARMACEUTICALS the worldwide rights of LEUKOTAC®

LEUKOTAC® is an immunotherapy antibody with clinical benefits in steroid-resistant acute Graft-versus-Host Disease

 

 

  • In a recent clinical study, it has shown a - favorable risk/benefit profile, supporting the experience already obtained with LEUKOTAC® in nearly 1,200 patients with acute graft-versus-host disease (aGvHD).

 

  • Developed to date by JAZZ PHARMACEUTICALS, LEUKOTAC® has received an orphan designation in Europe and the United States.

 

  • ELSALYS BIOTECH has initiated discussion with the European health authorities (EMA) and will engage in regulatory interactions with the FDA in 2018.

 

Lyon, FRANCE, October 12, 2017, ELSALYS BIOTECH, a new player in immuno-oncology, has acquired from JAZZ PHARMACEUTICALS the development and commercialization rights of LEUKOTAC® (inolimomab), a monoclonal antibody that has recently demonstrated its clinical superiority in the treatment of Steroid-Resistant acute Graft-versus-Host Disease (steroid-resistant aGvHD), an orphan disease with very poor prognosis.

 

 

Read the press release